A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD).

被引：0
|
作者：
Gotlib, J. R.
Kluin-Nelemans, H.
Mauro, M. J.
Hermine, O.
Hexner, E. O.
Lipton, J. H.
Awan, F. T.
Nikolova, Z. G.
Gross, S. H.
Dutreix, C.
Dharan, B.
George, T.
Horny, P.
Akin, C.
Hartmann, K.
Valent, P.
Reiter, A.
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[4] Hop Necker Enfants Malad, Paris, France
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Georgia Hlth Sci Univ, Augusta, GA USA
[8] Novartis Pharmaceut AG, Basel, Switzerland
[9] Novartis Pharma AG, Basel, Switzerland
[10] Novartis Pharmaceut, Hanover, NH USA
[11] Inst Pathol, Ansbach, Germany
[12] Brigham & Womens Hosp, Boston, MA 02115 USA
[13] Univ Cologne, D-50931 Cologne, Germany
[14] Med Univ Vienna, Vienna, Austria
[15] Univ Med Mannheim, Mannheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps200
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS200
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Cassaday, Ryan D.
    Goy, Andre
    Advani, Suresh
    Chawla, Purvi
    Nachankar, Rajesh
    Gandhi, Mansi
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07): : 392 - 397
  • [22] Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
    Spigel, David R.
    Waterhouse, David M.
    Lane, Steve
    Legenne, Philippe
    Bhatt, Kamal
    CLINICAL LUNG CANCER, 2013, 14 (04) : 356 - 363
  • [23] AN OPEN-LABEL, SINGLE-ARM, PHASE I STUDY TO ASSESS SAFETY AND EFFECT OF OFATUMUMAB ON B-CELL COUNTS, COMPLEMENT, AND CYTOKINES/CHEMOKINES IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Patton, N.
    Lindeman, R.
    Butler, A.
    Kipps, T.
    Fang, L.
    Jewell, R.
    Laubscher, K.
    Lewis, E.
    Sedoti, D.
    Witman, P.
    Chan, G.
    HAEMATOLOGICA, 2013, 98 : 545 - 545
  • [24] Efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).
    Qian, Kun
    Hu, Bin
    He, Ming
    Wang, Zi-Tong
    Liu, Yu
    Liang, Hua-Gang
    Su, Zhi-Yong
    Cui, Yu-Shang
    Liu, Li-Jun
    Zhang, Yi
    CANCER RESEARCH, 2022, 82 (12)
  • [25] Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: A single-arm, open-label, multicenter, phase II study
    Shinoda, Masahiro
    Shinkai, Masaharu
    Hara, Yu
    Tomaru, Kouji
    Manabe, Saki
    Murakami, Syuji
    Saito, Haruhiro
    Kobayashi, Nobuaki
    Miyazawa, Naoki
    Nishikawa, Masanori
    Kaneko, Takeshi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (06) : 486 - 494
  • [26] Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
    Fenner, Martin
    Oing, Christoph
    Dieing, Annette
    Gauler, Thomas
    Oechsle, Karin
    Lorch, Anja
    Hentrich, Marcus
    Kopp, Hans-Georg
    Bokemeyer, Carsten
    Honecker, Friedemann
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (03) : 717 - 723
  • [27] Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
    Martin Fenner
    Christoph Oing
    Annette Dieing
    Thomas Gauler
    Karin Oechsle
    Anja Lorch
    Marcus Hentrich
    Hans-Georg Kopp
    Carsten Bokemeyer
    Friedemann Honecker
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 717 - 723
  • [28] Efficacy and safety of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer: Preliminary results of an open-label, single-arm, phase II study.
    Luo, Hao
    Jian, Dan
    Feng, Yan
    Zhong, Li
    Chen, Qian
    Guan, Wei
    Zhang, Shiheng
    Luo, Jiamin
    Yang, Xueqing
    Gong, Kan
    Xiong, Yanli
    Li, Mengxia
    Xu, Mingfang
    Pu, Yu
    Zhao, Liang
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] A Multicenter, Multicohort, Open-Label, Single-Arm per Cohort, Phase II Study to Assess the Efficacy and Safety of Tabelecleucel in Patients with EBV-Associated Diseases Using an Adaptive Two-Stage Study Design
    Prockop, S.
    Dinavahi, R.
    Navarro, W.
    Guzman-Becerra, N.
    Sun, Y.
    Gamelin, L.
    BLOOD, 2020, 136
  • [30] Efficacy and Safety of Lenalidomide, PD-1 Monoclonal Antibodies Combined with Orelabrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase II Study
    Wang, Lingling
    Huang, Yongfen
    Chen, Hui
    Xu, Hao
    Cheng, Yuexin
    Miao, Yuqing
    BLOOD, 2024, 144 : 6488 - 6489
12345